Literature DB >> 19757412

Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?

Gianluca Trifirò1, Antoine Pariente, Preciosa M Coloma, Jan A Kors, Giovanni Polimeni, Ghada Miremont-Salamé, Maria Antonietta Catania, Francesco Salvo, Anaelle David, Nicholas Moore, Achille Patrizio Caputi, Miriam Sturkenboom, Mariam Molokhia, Julia Hippisley-Cox, Carlos Diaz Acedo, Johan van der Lei, Annie Fourrier-Reglat.   

Abstract

PURPOSE: Data mining on electronic health records (EHRs) has emerged as a promising complementary method for post-marketing drug safety surveillance. The EU-ADR project, funded by the European Commission, is developing techniques that allow mining of EHRs for adverse drug events across different countries in Europe. Since mining on all possible events was considered to unduly increase the number of spurious signals, we wanted to create a ranked list of high-priority events.
METHODS: Scientific literature, medical textbooks, and websites of regulatory agencies were reviewed to create a preliminary list of events that are deemed important in pharmacovigilance. Two teams of pharmacovigilance experts independently rated each event on five criteria: 'trigger for drug withdrawal', 'trigger for black box warning', 'leading to emergency department visit or hospital admission', 'probability of event to be drug-related', and 'likelihood of death'. In case of disagreement, a consensus score was obtained. Ordinal scales between 0 and 3 were used for rating the criteria, and an overall score was computed to rank the events.
RESULTS: An initial list comprising 23 adverse events was identified. After rating all the events and calculation of overall scores, a ranked list was established. The top-ranking events were: cutaneous bullous eruptions, acute renal failure, anaphylactic shock, acute myocardial infarction, and rhabdomyolysis.
CONCLUSIONS: A ranked list of 23 adverse drug events judged as important in pharmacovigilance was created to permit focused data mining. The list will need to be updated periodically as knowledge on drug safety evolves and new issues in drug safety arise. Copyright (c) 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19757412     DOI: 10.1002/pds.1836

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  68 in total

1.  Hypothesis-Free Search for Connections between Birth Month and Disease Prevalence in Large, Geographically Varied Cohorts.

Authors:  John P Borsi
Journal:  AMIA Annu Symp Proc       Date:  2017-02-10

2.  A drug-adverse event extraction algorithm to support pharmacovigilance knowledge mining from PubMed citations.

Authors:  Wei Wang; Krystl Haerian; Hojjat Salmasian; Rave Harpaz; Herbert Chase; Carol Friedman
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

3.  Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

Authors:  Peter M Wahl; Joshua J Gagne; Thomas E Wasser; Debra F Eisenberg; J Keith Rodgers; Gregory W Daniel; Marcus Wilson; Sebastian Schneeweiss; Jeremy A Rassen; Amanda R Patrick; Jerry Avorn; Rhonda L Bohn
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

4.  A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.

Authors:  Mickael Arnaud; Francesco Salvo; Ismaïl Ahmed; Philip Robinson; Nicholas Moore; Bernard Bégaud; Pascale Tubert-Bitter; Antoine Pariente
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

5.  A Multiagent System for Integrated Detection of Pharmacovigilance Signals.

Authors:  Vassilis Koutkias; Marie-Christine Jaulent
Journal:  J Med Syst       Date:  2015-11-21       Impact factor: 4.460

6.  Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; Susan Gruber; Ivan Zorych; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

Review 7.  Desideratum for evidence based epidemiology.

Authors:  J Marc Overhage; Patrick B Ryan; Martijn J Schuemie; Paul E Stang
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

8.  Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey.

Authors:  Paul E Stang; Patrick B Ryan; J Marc Overhage; Martijn J Schuemie; Abraham G Hartzema; Emily Welebob
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

9.  Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.

Authors:  Patrick B Ryan; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

10.  A comparison of the empirical performance of methods for a risk identification system.

Authors:  Patrick B Ryan; Paul E Stang; J Marc Overhage; Marc A Suchard; Abraham G Hartzema; William DuMouchel; Christian G Reich; Martijn J Schuemie; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.